v3.26.1
Segment Information (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Abstract]            
Number of operating segments | segment         1  
Number of reportable segments | segment         1  
Segment Reporting [Line Items]            
Product revenue, net $ 44,745   $ 12,455   $ 65,491 $ 21,181
PK activator (PYRUKYND®/AQVESME™) direct expenses - research and development (100,754)   (91,940)   (181,902) (164,683)
Total selling, general and administrative expenses (51,547)   (45,869)   (99,851) (87,396)
Net loss (100,703) $ (99,111) (112,020) $ (89,289) (199,814) (201,309)
Reportable Segment            
Segment Reporting [Line Items]            
PK activator (PYRUKYND®/AQVESME™) direct expenses - research and development (25,849)   (29,809)   (49,754) (51,130)
Compensation and related expenses - research and development (30,352)   (27,594)   (67,141) (60,584)
Total selling, general and administrative expenses (51,547)   (45,869)   (99,851) (87,396)
Other segment expenses (37,700)   (21,203)   (48,559) (23,380)
Net loss (100,703)   (112,020)   (199,814) (201,309)
Product revenue, net            
Segment Reporting [Line Items]            
Product revenue, net 44,745   12,455   65,491 21,181
Product revenue, net | United States            
Segment Reporting [Line Items]            
Product revenue, net 40,917   12,151   59,768 20,877
Product revenue, net | Rest of world            
Segment Reporting [Line Items]            
Product revenue, net 3,828   304   5,723 304
Product revenue, net | Reportable Segment | United States            
Segment Reporting [Line Items]            
Product revenue, net 40,917   12,151   59,768 20,877
Product revenue, net | Reportable Segment | Rest of world            
Segment Reporting [Line Items]            
Product revenue, net $ 3,828   $ 304   $ 5,723 $ 304